By attending this presentation, you will learn key strategies for:
- Advances in biomolecule analysis
- How you can improve data quality, sensitivity and resolution for metal-sensitive molecules (for small molecule and large biotherapeutic analysis)
- Advanced data processing technology for characterizing oligonucleotide products and impurities for LC-MS datasets
The shift towards biopharmaceuticals during the last decade posed some challenges in the construction of modern liquid chromatography systems, particularly addressing the problem of non-specific interactions, making the development of reproducible analytical methods a challenge.
This presentation covers and discusses the latest advances in liquid chromatography technology to minimize the effect of non-specific interactions. The discussion ranges from the basics of 'metal-sensitive' molecules to the method development strategies for the analysis of biomolecules. We provide a comprehensive overview of the major analytical challenges that could be faced when an accurate analysis is required for 'metal-sensitive' compounds, and we discuss the best countermeasures that can be adopted to ensure 'method robustness'. Moreover, we describe efficient data processing solutions for the characterization of oligonucleotide products and impurities for LC-MS datasets.
What you need to know:
Date: 14 December, 2023
Broadcast #1: 14 December – starting at 9 am GMT (London) / 10 am CET (Paris/Berlin)
Broadcast #2: 14 December – starting at 10 am PST (Los Angeles) / 12 pm CST (Chicago) / 1 pm EST (New York)
Duration: Approximately 40 minutes
Raymond Wong, MChem, Ph.D., MRSC
Senior Product Manager and National Sales Manager, Shimadzu UK Limited
Raymond Wong has over 20 years’ experience working within the analytical, purification and pharmaceutical industry. Dr Wong started as a synthetic organic chemist where early projects included investigating new fluorinated compounds with Ineos Fluor for early OLED technology. He was later involved with synthesizing modified oligonucleotides for antisense therapeutics, before transitioning to producing dynamic combinatorial libraries to investigate Sequencing by Synthesis (SbS). Following several diverse pharma campaigns within a contract laboratory, Raymond moved to Phenomenex to support method development across different sectors before joining Shimadzu over 8 years ago allowing him to collaborate with people looking to progress their research.